Q301--Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31

STATEMENT OF WORK (SOW) for Reference Laboratory Services for specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies BACKGROUND The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The contractor shall provide MRD testing of an FDA-cleared, next generation sequencing (NGS)-based assay for blood and bone marrow samples from patients diagnosed with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (B-ALL). Testing shall be performed at the contractor s CLIA-certified (requirement) and CAP-accredited (or equivalent; requirement) reference laboratory and include full interpretation and reporting of results to VHAPORHCS clinicians. This full-service Reference Laboratory contract will provide services required for specimen testing, interpretation, testing supplies, and customer service. This requirement will ensure accurate and timely test results are made available to healthcare providers which will ensure high quality healthcare is provided to the Veterans at the VA Portland Health Care System. SCOPE The objective of this agreement is to provide VHAPORHCS with access to FDA-cleared and clinically validated MRD testing to support direct patient care within the Hematology/Oncology and Pathology and Laboratory Medicine Services (PALMS), ensuring accurate disease monitoring and outcome assessment for veterans undergoing cancer therapy. The contractor shall: Provide MRD testing for the following specimen and disease types: Bone marrow aspirate or peripheral blood for: Multiple Myeloma (MM) Chronic Lymphocytic Leukemia (CLL) B-cell Acute Lymphoblastic Leukemia (B-ALL) FFPE Bone Marrow tissue (as applicable) Please see Attachment A to this Statement of Work (SOW) for the test and quantities required by VAPORHCS. Perform testing within the contractor s CLIA-certified, CAP-accredited (or equivalent) laboratory using FDA-cleared protocols. Provide average turnaround time shall be (6) business days from receipt of specimen. Provide secure electronic results via a vendor-managed portal and fax reports directly to designated VA clinicians. Maintain a customer-accessible results portal for tracking orders and retrieving historical patient data. Provide technical support for order management and result interpretation. Ensure all testing is performed using validated instruments, reagents, and methodologies per FDA clearance and CLIA/CAP (or equivalent) standards. The Reference Laboratory shall also provide the following support services: supplies, customer service, reporting services, and verification of certification. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following: Requisition forms or agreed computer ordering system Specimen containers & collection kits Specimen requirements for specimen collection & specimen processing Methodologies and reference ranges Expected turn-around times All forms, including authorization of consent for genetic testing, informed consent, and chain of custody. The VAPORHCS requires that the Reference laboratory provide technical and consultative support as it relates to any results provided by the vendor. The vendor shall identify on Attachment A, whether the testing is performed in-house or sent out/referred to an alternate lab, not owned by the vendor. Clinical Application and Importance: The MRD assay is clinically essential for identifying and quantifying MRD in patients treated for hematologic malignancies. MRD detection is a powerful biomarker...